

Anti-CD19 (Inebilizumab), Humanized Antibody

rev 12/20

CATALOG NO.: A2173-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized afucosylated monoclonal antibody that is directed against CD19. CD19 is a cell surface antigen that is expressed on pre-, mature and malignant B lymphocytes. It is required for proliferation, differentiation, activation of B cells, and antibody production. Although the precise mechanism is not known, it is presumed that the antibody binds to CD19 located on the malignant B cell surface and results in antibody-mediated cellular cytotoxicity. The original drug received approval from the FDA in 2020 to treat neuromyelitis optica spectrum disorder (NMOSD) in patients who were anti-aquaporin 4 (AQP4) positive

ALTERNATE NAMES: MEDI-551, MEDI 551, MEDI551, B4, CVID3

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human CD19

CAS NUMBER: 1299440-37-1

MOLECULAR WEIGHT: 149 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)

Anti-CD20 (Ofatumumab), Human IgG1 Antibody (A2172)

Anti-IgE (Omalizumab), Humanized Antibody (A2145)

Anti-C5 (Eculizumab), Humanized Antibody (A2138)

Anti-CD20 (Rituximab), Chimeric Antibody (A1049)

FOR RESEARCH USE ONLY! Not to be used on humans.